MEG3 Human shRNA Lentiviral Particle (Locus ID 55384)

CAT#: TL320132V

MEG3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL320132B virus into HEK293 cells. TL320132B virus was prepared using lenti-shRNA TL320132B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL320132D] virus into HEK293 cells. [TL320132D] virus was prepared using lenti-shRNA [TL320132D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 55384
• Synonyms: FP504; GTL2; LINC00023; NCRNA00023; onco-lncRNA-83; prebp1; PRO0518; PRO2160
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NR_002766, NR_003530, NR_003531, NR_033358, NR_033359, NR_033360, NR_046464, NR_046465, NR_046466, NR_046467, NR_046468, NR_046469, NR_046470, NR_046471, NR_046472, NR_046473, BC023543, BC036882, BC051294, BC062783, BC092509
• Summary: This gene is a maternally expressed imprinted gene. Multiple alternatively spliced transcript variants have been transcribed from this gene and all of them are long non-coding RNAs (lncRNAs). This gene is expressed in many normal tissues, but its expression is lost in multiple cancer cell lines of various tissue origins. It inhibits tumor cell proliferation in vitro. It also interacts with the tumor suppressor p53, and regulates p53 target gene expression. Its deletion enhances angiogenesis in vivo. Many experimental evidences demonstrate that this gene is a lncRNA tumor suppressor. [provided by RefSeq, Mar 2012]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).